Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
Figure 1
The unadjusted Kaplan-Meier curves showing cumulative incidence of all-cause mortality comparing patients treated with GP IIb/IIIa inhibitors to those not treated with them. Mortality was significantly improved amongst patients treated with GP IIb/IIIa inhibitors ().
